Stada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations
Coherus Looking To Refile By End Of Year
Executive Summary
With one foot already in oncology, biosimilars player Coherus is looking to make a splash in ophthalmology with ambitions to launch rivals to Lucentis and Eylea, as well as Avastin, in the US in the coming years. The US-based firm has acknowledged the competition it faces for biosimilars to Lucentis as Bausch Health picked up rights to Stada and Xbrane’s candidate earlier this month.
You may also be interested in...
Samsung Bioepis First To File EU Lucentis Rival
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.
Formycon Chief Sees COVID-19 Boosting Biosimilars
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
Xbrane And Stada’s Ranibizumab Snapped Up In North America
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.